Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Aytu Biopharma (AYTU) Net Income towards Common Stockholders: 2011-2025

Historic Net Income towards Common Stockholders for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $620,000.

  • Aytu Biopharma's Net Income towards Common Stockholders rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • Per Aytu Biopharma's latest filing, its Net Income towards Common Stockholders stood at $620,000 for FY2025, which was up 118.65% from -$3.3 million recorded in FY2024.
  • Aytu Biopharma's 5-year Net Income towards Common Stockholders high stood at $620,000 for FY2025, and its period low was -$108.8 million during FY2022.
  • In the last 3 years, Aytu Biopharma's Net Income towards Common Stockholders had a median value of -$3.3 million in 2024 and averaged -$6.6 million.
  • Per our database at Business Quant, Aytu Biopharma's Net Income towards Common Stockholders plummeted by 327.93% in 2021 and then soared by 118.65% in 2025.
  • Aytu Biopharma's Net Income towards Common Stockholders (Yearly) stood at -$58.3 million in 2021, then slumped by 86.62% to -$108.8 million in 2022, then skyrocketed by 84.21% to -$17.2 million in 2023, then surged by 80.65% to -$3.3 million in 2024, then spiked by 118.65% to $620,000 in 2025.